Cingulate Wins Patent for Trimodal Anxiety Tablet
The U.S. Patent and Trademark Office issued a patent to Cingulate Inc. covering a buspirone tablet that releases medication at three set times.
Updated on Nov. 21, 2026 in Mental Health

The U.S. Patent and Trademark Office issued U.S. Patent No. 12,797,335, titled Trimodal, Precision-Timed Release Tablet, to Cingulate Inc. on November 17, 2026. The patent covers a buspirone tablet formulation, an FDA-approved anxiety treatment, that releases medication at three predetermined times from a single tablet.
Why it matters
The patent supports Cingulate's planned development of CTx-2103 and protects a dosing approach aimed at delivering medication at multiple points in the day. The company's broader pipeline depends on its CTx-1301 application, which received a Complete Response Letter from the FDA in June 2026.
The patent covers a tablet-in-tablet design using an Erosion Barrier Layer licensed from BDD Pharma that controls drug release timing. Clinical outcomes for the three-release formulation have not been reported.
The players
Cingulate Inc.
Cingulate is a clinical-stage pharmaceutical company developing precision-timed release formulations for central nervous system conditions.
The details
The formulation enrobes a drug-containing core in an Erosion Barrier Layer that erodes at a controlled rate until the drug is released. Cingulate completed a proof-of-concept study using scintigraphic imaging to track tablet transit through the gastrointestinal tract.
Timeline
May 31, 2026: PDUFA target action date for the CTx-1301 application.
June 1, 2026: FDA issued a Complete Response Letter for CTx-1301.
November 17, 2026: USPTO issued the trimodal tablet patent.
December 2026 to January 2027: Expected window for CTx-1301 resubmission.
Second half of 2027: Anticipated CTx-1301 commercialization if approved.
Big Picture
The patent extends protection for buspirone, an anxiety medication approved decades ago, through a new precision-timed release design. This follows a broader industry pattern of reformulating established drugs to improve dosing schedules.
For people living with anxiety, this patent signals a possible future option with a dosing schedule designed to release medication at set times. Any product based on it would still require FDA approval before reaching pharmacies.
The takeaway
Patent grants show where drug developers are investing, but they do not confirm a product is safe or effective. Readers should watch for FDA decisions and clinical data before drawing conclusions about new anxiety treatments.
What happens next
Cingulate expects to resubmit the CTx-1301 application between December 2026 and January 2027, and anticipates commercialization in the second half of 2027 if approved.
Further reading
For related coverage, see Mental Health reporting.
Source note: This article includes information reported by Pharmabiz.






